ホーム > 医療関係者・学生のみなさま >業績集他

業績集他

2024年 | 2023年 | 2022年 | 2021年 | 2020年 | 2019年 | 2018年 | 2017年 | 2016年 | 2015年 | 2014年 | 2013年｜2012年 | 2011年

2023年　業績

【原著論文・症例報告】

1. Yoshida Y, Fujiwara M, Kinoshita M, Sada K, Miyamoto S, Ozeki Y, Iwamoto M,
   Mori Y, Nagai S, Matsuda N, Noguchi T, Okamoto M, Gotoh K, Masaki T, Shibata H. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism. Hypertens Res. Online ahead of print
2. Sada K, Yoshida Y, Shibuta K, Kimoto K, Miyamoto S, Ozeki Y, Okamoto M, Gotoh
   K, Masaki T, Yokoyama K, Kubota T, Shibata H. Associations of Diabetic
   Retinopathy Severity With High Ambulatory Blood Pressure and Suppressed Serum Renin Levels. J Clin Endocrinol Metab108(12):e1624-e1632
3. Yoshida Y, Fujiki R, Kinoshita M, Sada K, Miyamoto S, Ozeki Y, Mori Y,
   Matsuda N, Noguchi T, Nakama H, Okamoto M, Gotoh K, Masaki T, Shibata H. Importance of dietary salt restriction for patients with primary aldosteronism
   during treatment with mineralocorticoid receptor antagonists: The potential
   importance of post-treatment plasma renin levels. Hypertens Res. 46(1):100-107.
4. Miyamoto S, Yoshida Y, Ozeki Y, Okamoto M, Gotoh K, Masaki T, Nishida H,
   Fujinami H, Shin T, Daa T, Asayama Y, Shibata H. Pitfalls in the diagnosis and
   treatment of a hypertensive patient with unilateral primary aldosteronism and
   contralateral pheochromocytoma: a case report. BMC Endocr Disord. 16;23(1):44
5. Shibata H. Adrenal ablation therapy for unilateral primary aldosteronism:
   pros and cons. Hypertens Res. 46(3):787-789
6. Yoshida Y, Shibata H. Visceral fat: a bad companion for mineralocorticoid receptor overactivation. Hypertens Res.46(5):1168-1170.
7. Yoshida Y, Shibata H. Recent progress in the diagnosis and treatment of primary aldosteronism. Hypertens Res. 46(7):1738-1744.
8. Gotoh K, Shibata H. Association between the gut microbiome and the renin-
   angiotensin-aldosterone system: a possible link via the activation of the immune system. Hypertens Res. 46(10):2315-2317.
9. Ozeki Y, Shibata H. Utility of 18-hydroxycortisol and 18-oxocortisol: potential markers of aldosterone-producing adenomas. Hypertens Res. 46(10):2433-2435
10. Yoshida Y, Shibata H. Fat mass: the most sensitive predictor of persistent hypertension in unilateral primary aldosteronism. Hypertens Res. 46(6): 1444-1446
11. Yoshida Y, Shibata H. No "U-shaped" associations of estimated glomerular filtration rate with adverse cardiovascular outcomes in patients with primary
    aldosteronism. Hypertens Res. Online ahead of print
12. Maeshima K, Abe T, Imada C, Ozaki T, Shibata H. Anifrolumab for refractory lupus erythematosus panniculitis in systemic lupus erythematosus. Rheumatology (Oxford). Online ahead of print
13. Nakata T, Fukuda A, Ojiro K, Matsuyama K, Masaki T, Itoh H, Shibata H. A Questionnaire Survey of Prescription Preferences and Leftover Medication Conversations: Comparisons Among Kidney Disease Patients and Healthcare Professionals. Cureus. 15(9): e45842. 
14. Nakata T, Tanigawa M, Fukuda A, Shibata H. Histological classification of Japanese IgA nephropathy with a small number of glomeruli using Bayes' theorem. Sci Rep. 13(1):18663
15. Fukuda A, Suzuki M, Kurimoto R, Okita J, Uchida H, Kudo A, Nakata T, Sato Y, Shibata H. Urinary sediment podocin mRNA excretion in healthy adults. American Society of Nephrology.
16. Kudo A, Fukuda A, Okita J, Uchida H, Nakata T, Uesugi N, Shibata H. A first case of ANCA-associated vasculitis with IgG4-related disease treated with C5a receptor inhibitor avacopan. American Society of Nephrology.
17. Suzuki M, Fukuda A, Kurimoto R, Uchida H, Kudo A, Nakata T, Shibata H. SGLT2 inhibitor suppresses progression of obesity-related nephropathy induced by podocyte hypertrophic stress. American Society of Nephrology.
18. Hiroki U, Fukuda A, Okita J, Kudo A, Nakata T, Uesugi N, Shibata H. A case of IgG4-related kidney disease with a rare renal cyst. American Society of Nephrology.
19. Okita J, Nakata T, Uchida H, Kudo A, Fukuda A, Shibata H. Predictive Model of the Time to Renal Replacement Therapy Using Machine Learning. American Society of Nephrology.
20. Tanaka A, Shibata H, Imai T, Yoshida H, Miyazono M, Takahashi N, Fukuda D, Okada Y, Teragawa H, Suwa S, Kida K, Moroi M, Taguchi I, Toyoda S, Shimabukuro M, Tanabe K, Tanaka K, Nangaku M, Node K; FIVE-STAR trial investigators. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR). Cardiovasc Diabetol. 22(1):194.
21. Yokota K, Shibata H, Kurihara I, Itoh H, Sone M. CASZ1: a promising factor modulating aldosterone biosynthesis and mineralocorticoid receptor activity. Hypertens Res. 46(2):417-420.
22. Jo R, Shibata H, Kurihara I, Yokota K, Kobayashi S, Murai-Takeda A, Mitsuishi Y, Hayashi T, Nakamura T, Itoh H. Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification. Hypertens Res. 46(1): 19-31/ Correction: 46(3):814. 
23. Ichihara A, Shibata H, Hayashi K, Saito I. In memoriam: a tribute to Takao Saruta, MD, PhD. Hypertens Res.